Allogene Therapeutics, Inc.
NMS: ALLOLive Quote
📈 ZcoreAI Score
Our AI model analyzes Allogene Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ALLO Z-Score →About Allogene Therapeutics, Inc.
Healthcare
Biotechnology
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops a pipeline of multiple allogeneic CAR T cell product candidates utilizing protein engineering, gene editing, gene insertion, and advanced proprietary T cell manufacturing technologies. The company is also developing cemacabtagene ansegedleucel (cema-cel), an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma (LBCL). In addition, it develops ALLO-316, an engineered allogeneic CAR T cell product candidate that targets CD70 to treat renal cell carcinoma (RCC); and ALLO-329, an engineered allogeneic CAR T cell product candidate that targets both CD19 and CD70 for the treatment of autoimmune diseases (AID), such as systemic lupus erythematosus (SLE), idiopathic inflammatory myopathies (IIM), and systemic sclerosis (SSc). The company was incorporated in 2017 and is headquartered in South San Francisco, California.
📊 Fundamental Analysis
Allogene Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -53.4%, which indicates that capital utilization is currently under pressure.
At a current price of $2.72, ALLO currently trades near the top of its 52-week range (89%) (Range: $0.86 - $2.95).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$663.08M
Trailing P/E
--
Forward P/E
-3.61
Beta (5Y)
0.54
52W High
$2.95
52W Low
$0.86
Avg Volume
5.83M
Day High
Day Low